JP2001513483A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001513483A5 JP2001513483A5 JP2000502772A JP2000502772A JP2001513483A5 JP 2001513483 A5 JP2001513483 A5 JP 2001513483A5 JP 2000502772 A JP2000502772 A JP 2000502772A JP 2000502772 A JP2000502772 A JP 2000502772A JP 2001513483 A5 JP2001513483 A5 JP 2001513483A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- local anesthetic
- compound
- medicament
- headache
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 levo-ropivacaine Chemical compound 0.000 description 23
- 239000003589 local anesthetic agent Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 12
- 206010019233 Headaches Diseases 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 7
- 208000017376 neurovascular disease Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 229960001549 ropivacaine Drugs 0.000 description 6
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229960003150 bupivacaine Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229960004288 levobupivacaine Drugs 0.000 description 3
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 3
- 229960002409 mepivacaine Drugs 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229960003976 etidocaine Drugs 0.000 description 2
- 239000000374 eutectic mixture Substances 0.000 description 2
- DHCUQNSUUYMFGX-UHFFFAOYSA-N hydroxytetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C(O)=C1 DHCUQNSUUYMFGX-UHFFFAOYSA-N 0.000 description 2
- 229950000638 hydroxytetracaine Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- HZGRVVUQEIBCMS-HTRCEHHLSA-N (1s,5r)-8-methyl-8-azabicyclo[3.2.1]oct-3-ene-4-carboxylic acid Chemical compound C1C=C(C(O)=O)[C@H]2CC[C@@H]1N2C HZGRVVUQEIBCMS-HTRCEHHLSA-N 0.000 description 1
- 0 **(CC1)CCC1(C(N(*)*)=O)C1=CCCC=C1 Chemical compound **(CC1)CCC1(C(N(*)*)=O)C1=CCCC=C1 0.000 description 1
- ZLMQPGUWYWFPEG-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-butoxybenzoate Chemical compound CCCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC ZLMQPGUWYWFPEG-UHFFFAOYSA-N 0.000 description 1
- GHSCYMOJHVOGDJ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-hydroxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1O GHSCYMOJHVOGDJ-UHFFFAOYSA-N 0.000 description 1
- QNIUOGIMJWORNZ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-butoxybenzoate Chemical compound CCCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 QNIUOGIMJWORNZ-UHFFFAOYSA-N 0.000 description 1
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 1
- SQSPRWMERUQXNE-UHFFFAOYSA-N Guanylurea Chemical class NC(=N)NC(N)=O SQSPRWMERUQXNE-UHFFFAOYSA-N 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 229950008211 ambucaine Drugs 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- ZYHGIAPHLSTGMX-UHFFFAOYSA-N beta-Eucaine Chemical compound C1C(C)(C)NC(C)CC1OC(=O)C1=CC=CC=C1 ZYHGIAPHLSTGMX-UHFFFAOYSA-N 0.000 description 1
- 229960003369 butacaine Drugs 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- 229960000400 butamben Drugs 0.000 description 1
- 229960002463 butoxycaine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical class CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 1
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 1
- 229950010160 dimethocaine Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229950000998 hydroxyprocaine Drugs 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical class CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- LJQWYEFHNLTPBZ-UHFFFAOYSA-N metabutoxycaine Chemical compound CCCCOC1=C(N)C=CC=C1C(=O)OCCN(CC)CC LJQWYEFHNLTPBZ-UHFFFAOYSA-N 0.000 description 1
- 229950004316 metabutoxycaine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-XGUBFFRZSA-N methyl (1s,3s,4s,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-XGUBFFRZSA-N 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical class CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 description 1
- 229950007049 phenacaine Drugs 0.000 description 1
- 229960001045 piperocaine Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 1
- 229950011219 propipocaine Drugs 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
- KYBJXENQEZJILU-UHFFFAOYSA-N zolamine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CS1 KYBJXENQEZJILU-UHFFFAOYSA-N 0.000 description 1
- 229950006211 zolamine Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89719297A | 1997-07-21 | 1997-07-21 | |
| US08/897,192 | 1997-07-21 | ||
| US7284598P | 1998-01-28 | 1998-01-28 | |
| US60/072,845 | 1998-01-28 | ||
| US8455998P | 1998-05-06 | 1998-05-06 | |
| US60/084,559 | 1998-05-06 | ||
| PCT/US1998/014870 WO1999003473A1 (en) | 1997-07-21 | 1998-07-17 | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001513483A JP2001513483A (ja) | 2001-09-04 |
| JP2001513483A5 true JP2001513483A5 (https=) | 2006-01-05 |
| JP4521117B2 JP4521117B2 (ja) | 2010-08-11 |
Family
ID=27372174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000502772A Expired - Fee Related JP4521117B2 (ja) | 1997-07-21 | 1998-07-17 | 偏頭痛、群発性頭痛、緊張性頭痛、血管疾患に伴う頭痛、耳鳴りまたは筋肉性頭痛を治療するための医薬 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0999839B1 (https=) |
| JP (1) | JP4521117B2 (https=) |
| KR (1) | KR20010022041A (https=) |
| CN (1) | CN1267219A (https=) |
| AR (1) | AR013240A1 (https=) |
| AT (1) | ATE269702T1 (https=) |
| AU (1) | AU8574398A (https=) |
| BR (1) | BR9810773A (https=) |
| CA (1) | CA2297097C (https=) |
| DE (1) | DE69824730T2 (https=) |
| EE (1) | EE200000050A (https=) |
| HU (1) | HUP0003953A3 (https=) |
| ID (1) | ID24903A (https=) |
| IL (2) | IL134087A0 (https=) |
| IS (1) | IS5349A (https=) |
| NO (1) | NO20000293L (https=) |
| PL (1) | PL338176A1 (https=) |
| SK (1) | SK187899A3 (https=) |
| TR (1) | TR200000149T2 (https=) |
| WO (1) | WO1999003473A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704349D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
| JP4632499B2 (ja) * | 1999-08-26 | 2011-02-16 | 武田薬品工業株式会社 | 鼻粘膜付着マトリックス |
| AU2100901A (en) * | 1999-12-15 | 2001-06-25 | Bruce H. Levin | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
| GB9930083D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| US7117033B2 (en) | 2000-05-08 | 2006-10-03 | Brainsgate, Ltd. | Stimulation for acute conditions |
| AU5662001A (en) | 2000-05-08 | 2001-11-20 | Brainsgate Ltd. | Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow |
| US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
| US7146209B2 (en) | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
| US6853858B2 (en) | 2000-05-08 | 2005-02-08 | Brainsgate, Ltd. | Administration of anti-inflammatory drugs into the central nervous system |
| WO2004043218A2 (en) | 2002-11-14 | 2004-05-27 | Brainsgate Ltd. | Surgical tools and techniques for stimulation |
| US7561919B2 (en) | 2002-11-14 | 2009-07-14 | Brainsgate Ltd. | SPG stimulation via the greater palatine canal |
| WO2005062829A2 (en) | 2003-12-19 | 2005-07-14 | Advanced Bionics Corporation | Skull-mounted electrical stimulation system and method for treating patients |
| US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
| US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
| US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
| US7592371B2 (en) | 2004-08-18 | 2009-09-22 | Medrx Co., Ltd. | External preparation |
| AU2009274137B2 (en) * | 2008-07-21 | 2013-10-31 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| DE102008037682A1 (de) | 2008-08-14 | 2010-04-08 | Strackharn, Klaus, Dr.med. | Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen |
| US9889109B2 (en) | 2012-09-28 | 2018-02-13 | St. Renatus, Llc | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines |
| CN103432378A (zh) * | 2013-08-15 | 2013-12-11 | 吕清华 | 一种治疗神经血管性头痛的中药 |
| US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| CN113573705A (zh) * | 2018-12-19 | 2021-10-29 | 诺迪克控股公司 | 鼻内利多卡因的治疗组合物 |
| WO2020152212A1 (en) * | 2019-01-22 | 2020-07-30 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Local anesthetic for the treatment of neurological symptoms resulting from brain dysfunctions |
| GB2628149A (en) * | 2023-03-16 | 2024-09-18 | Lee Nathaniel Wurie | Nasal spray for performing sphenopalatine ganglion block |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9321061D0 (en) * | 1993-10-13 | 1993-12-01 | Chiroscience Ltd | Analgestic agent and its use |
| DE19524691A1 (de) * | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen |
| DE19526019A1 (de) * | 1995-07-17 | 1997-01-23 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Kopfschmerzen |
| BE1009851A3 (fr) * | 1996-01-11 | 1997-10-07 | Thiebauld Charles Marie | Composition pharmaceutique pour le traitement des cephalees et son utilisation. |
| GB2315673A (en) * | 1996-08-01 | 1998-02-11 | Merck & Co Inc | Treatment of migraine |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| GB9704349D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
-
1998
- 1998-07-17 CN CN98808214A patent/CN1267219A/zh active Pending
- 1998-07-17 EP EP98936893A patent/EP0999839B1/en not_active Expired - Lifetime
- 1998-07-17 HU HU0003953A patent/HUP0003953A3/hu unknown
- 1998-07-17 IL IL13408798A patent/IL134087A0/xx active IP Right Grant
- 1998-07-17 AT AT98936893T patent/ATE269702T1/de not_active IP Right Cessation
- 1998-07-17 AU AU85743/98A patent/AU8574398A/en not_active Abandoned
- 1998-07-17 KR KR1020007000610A patent/KR20010022041A/ko not_active Withdrawn
- 1998-07-17 PL PL98338176A patent/PL338176A1/xx unknown
- 1998-07-17 DE DE69824730T patent/DE69824730T2/de not_active Expired - Lifetime
- 1998-07-17 TR TR2000/00149T patent/TR200000149T2/xx unknown
- 1998-07-17 JP JP2000502772A patent/JP4521117B2/ja not_active Expired - Fee Related
- 1998-07-17 WO PCT/US1998/014870 patent/WO1999003473A1/en not_active Ceased
- 1998-07-17 EE EEP200000050A patent/EE200000050A/xx unknown
- 1998-07-17 BR BR9810773-9A patent/BR9810773A/pt not_active IP Right Cessation
- 1998-07-17 CA CA002297097A patent/CA2297097C/en not_active Expired - Lifetime
- 1998-07-17 ID IDW20000123D patent/ID24903A/id unknown
- 1998-07-17 SK SK1878-99A patent/SK187899A3/sk unknown
- 1998-07-21 AR ARP980103565A patent/AR013240A1/es unknown
-
2000
- 2000-01-17 IL IL134087A patent/IL134087A/en not_active IP Right Cessation
- 2000-01-18 IS IS5349A patent/IS5349A/is unknown
- 2000-01-20 NO NO20000293A patent/NO20000293L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001513483A5 (https=) | ||
| DE69733611T2 (de) | Verfahren und potenzierte zusammensetzung zur behandlung von migräne | |
| RU2095062C1 (ru) | Блокатор синдрома отмены, являющегося результатом привыкания к чрезмерному потреблению лекарств или веществ, вызывающих привыкание, фармакологическая композиция на его основе и способ облегчения или предотвращения синдрома отмены | |
| EP0735859B1 (en) | A pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| US5116852A (en) | Treatment of sleep disorders | |
| US20020006435A1 (en) | Transdermal anesthetic and vasodilator composition and methods for topical administration | |
| CA2039055A1 (en) | Treatment of sinus headache | |
| CA2070685C (en) | Method for treating painful, inflammatory or allergic disorders | |
| AU2003291037A1 (en) | Analgesic uses of norketamine and ketamine/norketamine prodrugs | |
| CA2451566A1 (en) | Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury | |
| JP2003509349A5 (https=) | ||
| US20220323472A1 (en) | Anti-parasitic compounds for the treatment and prevention of viral diseases | |
| KR20010022041A (ko) | 뇌 신경혈관 장애 및 근육성 두통 억제용 조성물, 키트 및방법 | |
| CA2303815A1 (en) | N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain | |
| WINTON | Anesthesia for dermatologic surgery | |
| JPH0745405B2 (ja) | 鎮痛剤組成物 | |
| JP2001506652A (ja) | 眼の痛みを治療するためのκオピオイド・アゴニストの局所使用 | |
| US6284800B1 (en) | Methods and compositions for treatment of asthma | |
| US4973596A (en) | Method of administering a narcotic analgesic and dosage forms therefor | |
| JPS6034909A (ja) | いびき止め剤 | |
| JP2002509154A5 (https=) | ||
| Mayrhofer | Self-experiments with succinylcholine chloride | |
| CY1333A (en) | Pharmaceutical compositions containing cromoglycates | |
| JP2002523458A5 (https=) | ||
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére |